XML 92 R51.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segments of business and geographic areas (Tables) | 12 Months Ended
--- | ---
Dec. 29, 2024
Segment Reporting [Abstract] |
Schedule of Sales by Segment of Business |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2024 |  | 2023 |  | 2022 |  | ’24 vs. ’23 |  | ’23 vs. ’22
INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |
U.S. |  | $11,355 |  | 11,539 |  | 11,036 |  | (1.6) | % |  | 4.6 |
International |  | 6,473 |  | 6,513 |  | 5,899 |  | (0.6) |  |  | 10.4 |
Worldwide |  | 17,828 |  | 18,052 |  | 16,935 |  | (1.2) |  |  | 6.6 |
REMICADE |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,009 |  | 1,143 |  | 1,417 |  | (11.7) |  |  | (19.3) |
U.S. Exports |  | 98 |  | 147 |  | 204 |  | (33.0) |  |  | (28.0) |
International |  | 497 |  | 549 |  | 722 |  | (9.5) |  |  | (23.9) |
Worldwide |  | 1,605 |  | 1,839 |  | 2,343 |  | (12.8) |  |  | (21.5) |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,082 |  | 1,124 |  | 1,166 |  | (3.8) |  |  | (3.6) |
International |  | 1,108 |  | 1,073 |  | 1,017 |  | 3.3 |  |  | 5.4 |
Worldwide |  | 2,190 |  | 2,197 |  | 2,184 |  | (0.3) |  |  | 0.6 |
STELARA |  |  |  |  |  |  |  |  |  |
U.S. |  | 6,720 |  | 6,966 |  | 6,388 |  | (3.5) |  |  | 9.0 |
International |  | 3,641 |  | 3,892 |  | 3,335 |  | (6.4) |  |  | 16.7 |
Worldwide |  | 10,361 |  | 10,858 |  | 9,723 |  | (4.6) |  |  | 11.7 |
TREMFYA |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,443 |  | 2,147 |  | 1,844 |  | 13.7 |  |  | 16.5 |
International |  | 1,227 |  | 999 |  | 824 |  | 22.8 |  |  | 21.2 |
Worldwide |  | 3,670 |  | 3,147 |  | 2,668 |  | 16.6 |  |  | 17.9 |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  | 11 |  | 17 |  | (74.1) |  |  | (33.8) |
International |  | 0 |  | 0 |  | 0 |  | — |  |  | —
Worldwide |  | 3 |  | 11 |  | 17 |  | (74.1) |  |  | (33.8) |
Infectious Diseases |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,354 |  | 1,500 |  | 1,680 |  | (9.8) |  |  | (10.7) |
International |  | 2,042 |  | 2,918 |  | 3,769 |  | (30.0) |  |  | (22.6) |
Worldwide |  | 3,396 |  | 4,418 |  | 5,449 |  | (23.1) |  |  | (18.9) |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |
U.S. |  | 0 |  | 0 |  | 120 |  | — |  | *
International |  | 198 |  | 1,117 |  | 2,059 |  | (82.4) |  |  | (45.8) |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2024 |  | 2023 |  | 2022 |  | ’24 vs. ’23 |  | ’23 vs. ’22
Worldwide |  | 198 |  | 1,117 |  | 2,179 |  | (82.4) |  |  | (48.8) |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |
U.S. |  | 31 |  | 35 |  | 36 |  | (10.0) |  |  | (3.7) |
International |  | 1,241 |  | 1,115 |  | 972 |  | 11.2 |  |  | 14.8 |
Worldwide |  | 1,272 |  | 1,150 |  | 1,008 |  | 10.6 |  |  | 14.1 |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,311 |  | 1,446 |  | 1,494 |  | (9.4) |  |  | (3.2) |
International |  | 401 |  | 408 |  | 449 |  | (1.7) |  |  | (9.2) |
Worldwide |  | 1,712 |  | 1,854 |  | 1,943 |  | (7.7) |  |  | (4.6) |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |
U.S. |  | 11 |  | 19 |  | 30 |  | (41.0) |  |  | (34.5) |
International |  | 203 |  | 278 |  | 289 |  | (26.7) |  |  | (3.8) |
Worldwide |  | 214 |  | 297 |  | 318 |  | (27.6) |  |  | (6.7) |
Neuroscience |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,398 |  | 4,065 |  | 3,570 |  | 8.2 |  |  | 13.9 |
International |  | 2,718 |  | 3,076 |  | 3,323 |  | (11.6) |  |  | (7.5) |
Worldwide |  | 7,115 |  | 7,140 |  | 6,893 |  | (0.4) |  |  | 3.6 |
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |
U.S. |  | 134 |  | 230 |  | 151 |  | (41.7) |  |  | 52.5 |
International |  | 507 |  | 554 |  | 493 |  | (8.4) |  |  | 12.2 |
Worldwide |  | 641 |  | 783 |  | 644 |  | (18.1) |  |  | 21.6 |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,125 |  | 2,897 |  | 2,714 |  | 7.9 |  |  | 6.7 |
International |  | 1,097 |  | 1,218 |  | 1,426 |  | (9.9) |  |  | (14.6) |
Worldwide |  | 4,222 |  | 4,115 |  | 4,140 |  | 2.6 |  |  | (0.6) |
SPRAVATO |  |  |  |  |  |  |  |  |  |
U.S. |  | 929 |  | 589 |  | 328 |  | 57.8 |  |  | 79.7 |
International |  | 148 |  | 100 |  | 46 |  | 48.2 |  |  | *
Worldwide |  | 1,077 |  | 689 |  | 374 |  | 56.4 |  |  | 84.1 |
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |
U.S. |  | 210 |  | 349 |  | 376 |  | (39.8) |  |  | (7.3) |
International |  | 965 |  | 1,204 |  | 1,358 |  | (19.8) |  |  | (11.3) |
Worldwide |  | 1,175 |  | 1,553 |  | 1,734 |  | (24.3) |  |  | (10.4) |
Oncology |  |  |  |  |  |  |  |  |  |
U.S. |  | 10,854 |  | 8,462 |  | 6,930 |  | 28.3 |  |  | 22.1 |
International |  | 9,926 |  | 9,199 |  | 9,052 |  | 7.9 |  |  | 1.6 |
Worldwide |  | 20,781 |  | 17,661 |  | 15,983 |  | 17.7 |  |  | 10.5 |
CARVYKTI |  |  |  |  |  |  |  |  |  |
U.S. |  | 869 |  | 469 |  | 133 |  | 85.2 |  | *
International |  | 94 |  | 30 |  | — |  | * |  | *
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2024 |  | 2023 |  | 2022 |  | ’24 vs. ’23 |  | ’23 vs. ’22
Worldwide |  | 963 |  | 500 |  | 133 |  | 92.7 |  | *
DARZALEX |  |  |  |  |  |  |  |  |  |
U.S. |  | 6,588 |  | 5,277 |  | 4,210 |  | 24.8 |  |  | 25.4 |
International |  | 5,082 |  | 4,467 |  | 3,767 |  | 13.8 |  |  | 18.6 |
Worldwide |  | 11,670 |  | 9,744 |  | 7,977 |  | 19.8 |  |  | 22.2 |
ERLEADA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,282 |  | 1,065 |  | 968 |  | 20.3 |  |  | 10.0 |
International |  | 1,717 |  | 1,322 |  | 913 |  | 29.8 |  |  | 44.8 |
Worldwide |  | 2,999 |  | 2,387 |  | 1,881 |  | 25.6 |  |  | 26.9 |
IMBRUVICA |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,020 |  | 1,051 |  | 1,390 |  | (3.0) |  |  | (24.4) |
International |  | 2,018 |  | 2,214 |  | 2,394 |  | (8.8) |  |  | (7.5) |
Worldwide |  | 3,038 |  | 3,264 |  | 3,784 |  | (6.9) |  |  | (13.7) |
TECVAYLI |  |  |  |  |  |  |  |  |  |
U.S. |  | 418 |  | 334 |  | 12 |  | 25.3 |  |  | *
International |  | 131 |  | 61 |  | 3 |  | * |  | *
Worldwide |  | 549 |  | 395 |  | 15 |  | 38.8 |  |  | *
ZYTIGA /abiraterone acetate |  |  |  |  |  |  |  |  |  |
U.S. |  | 34 |  | 50 |  | 74 |  | (32.2) |  |  | (32.1) |
International |  | 597 |  | 837 |  | 1,696 |  | (28.6) |  |  | (50.7) |
Worldwide |  | 631 |  | 887 |  | 1,770 |  | (28.8) |  |  | (49.9) |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |
U.S. |  | 643 |  | 215 |  | 144 |  | * |  | 49.3 |
International |  | 288 |  | 269 |  | 280 |  | 7.1 |  |  | (3.9) |
Worldwide |  | 931 |  | 484 |  | 423 |  | 92.5 |  |  | 14.4 |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,143 |  | 2,697 |  | 2,346 |  | 16.5 |  |  | 15.0 |
International |  | 1,140 |  | 1,117 |  | 1,071 |  | 2.0 |  |  | 4.3 |
Worldwide |  | 4,282 |  | 3,815 |  | 3,417 |  | 12.3 |  |  | 11.6 |
OPSUMIT |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,520 |  | 1,292 |  | 1,132 |  | 17.7 |  |  | 14.1 |
International |  | 664 |  | 681 |  | 651 |  | (2.4) |  |  | 4.6 |
Worldwide |  | 2,184 |  | 1,973 |  | 1,783 |  | 10.7 |  |  | 10.6 |
UPTRAVI |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,511 |  | 1,326 |  | 1,104 |  | 13.9 |  |  | 20.1 |
International |  | 307 |  | 255 |  | 218 |  | 20.1 |  |  | 17.3 |
Worldwide |  | 1,817 |  | 1,582 |  | 1,322 |  | 14.9 |  |  | 19.7 |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |
U.S. |  | 112 |  | 79 |  | 110 |  | 41.8 |  |  | (28.6) |
International |  | 169 |  | 182 |  | 202 |  | (6.9) |  |  | (10.3) |
Worldwide |  | 281 |  | 260 |  | 313 |  | 7.9 |  |  | (16.7) |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2024 |  | 2023 |  | 2022 |  | ’24 vs. ’23 |  | ’23 vs. ’22
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,866 |  | 2,906 |  | 3,042 |  | (1.4) |  |  | (4.5) |
International |  | 696 |  | 765 |  | 845 |  | (9.1) |  |  | (9.4) |
Worldwide |  | 3,562 |  | 3,671 |  | 3,887 |  | (3.0) |  |  | (5.5) |
XARELTO |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,373 |  | 2,365 |  | 2,473 |  | 0.3 |  |  | (4.4) |
International |  | — |  | — |  | — |  | — |  |  | — |
Worldwide |  | 2,373 |  | 2,365 |  | 2,473 |  | 0.3 |  |  | (4.4) |
OTHER |  |  |  |  |  |  |  |  |  |
U.S. |  | 494 |  | 541 |  | 569 |  | (8.8) |  |  | (5.0) |
International |  | 696 |  | 765 |  | 845 |  | (9.1) |  |  | (9.4) |
Worldwide |  | 1,189 |  | 1,306 |  | 1,414 |  | (8.9) |  |  | (7.6) |
TOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |
U.S. |  | 33,970 |  | 31,169 |  | 28,604 |  | 9.0 |  |  | 9.0 |
International |  | 22,994 |  | 23,590 |  | 23,959 |  | (2.5) |  |  | (1.5) |
Worldwide |  | 56,964 |  | 54,759 |  | 52,563 |  | 4.0 |  |  | 4.2 |
MEDTECH |  |  |  |  |  |  |  |  |  |
Cardiovascular (1) |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,513 |  | 3,633 |  | 2,169 |  | 24.2 |  |  | 67.5 |
International |  | 3,194 |  | 2,717 |  | 2,131 |  | 17.6 |  |  | 27.5 |
Worldwide |  | 7,707 |  | 6,350 |  | 4,300 |  | 21.4 |  |  | 47.7 |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,738 |  | 2,458 |  | 2,036 |  | 11.4 |  |  | 20.7 |
International |  | 2,529 |  | 2,230 |  | 1,901 |  | 13.4 |  |  | 17.3 |
Worldwide |  | 5,267 |  | 4,688 |  | 3,937 |  | 12.3 |  |  | 19.1 |
ABIOMED(2) |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,213 |  | 1,066 |  | 31 |  | 13.7 |  |  | *
International |  | 284 |  | 240 |  | — |  | 18.2 |  |  | *
Worldwide |  | 1,496 |  | 1,306 |  | 31 |  | 14.5 |  |  | *
SHOCKWAVE(3) |  |  |  |  |  |  |  |  |  |
U.S. |  | 442 |  | — |  | — |  | * |  | *
International |  | 122 |  | — |  | — |  | * |  | *
Worldwide |  | 564 |  | — |  | — |  | * |  | *
OTHER CARDIOVASCULAR(1) |  |  |  |  |  |  |  |  |  |
U.S. |  | 120 |  | 109 |  | 102 |  | 10.7 |  |  | 6.7 |
International |  | 260 |  | 247 |  | 230 |  | 5.3 |  |  | 7.3 |
Worldwide |  | 380 |  | 356 |  | 332 |  | 6.9 |  |  | 7.1 |
Orthopaedics |  |  |  |  |  |  |  |  |  |
U.S. |  | 5,689 |  | 5,525 |  | 5,321 |  | 3.0 |  |  | 3.8 |
International |  | 3,470 |  | 3,417 |  | 3,267 |  | 1.5 |  |  | 4.6 |
Worldwide |  | 9,158 |  | 8,942 |  | 8,587 |  | 2.4 |  |  | 4.1 |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2024 |  | 2023 |  | 2022 |  | ’24 vs. ’23 |  | ’23 vs. ’22
HIPS |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,057 |  | 996 |  | 943 |  | 6.2 |  |  | 5.6 |
International |  | 581 |  | 564 |  | 571 |  | 3.0 |  |  | (1.2) |
Worldwide |  | 1,638 |  | 1,560 |  | 1,514 |  | 5.0 |  |  | 3.0 |
KNEES |  |  |  |  |  |  |  |  |  |
U.S. |  | 922 |  | 896 |  | 851 |  | 2.9 |  |  | 5.3 |
International |  | 623 |  | 559 |  | 508 |  | 11.3 |  |  | 10.2 |
Worldwide |  | 1,545 |  | 1,456 |  | 1,359 |  | 6.1 |  |  | 7.1 |
TRAUMA |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,013 |  | 1,949 |  | 1,882 |  | 3.3 |  |  | 3.6 |
International |  | 1,036 |  | 1,030 |  | 989 |  | 0.6 |  |  | 4.1 |
Worldwide |  | 3,049 |  | 2,979 |  | 2,871 |  | 2.3 |  |  | 3.8 |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,696 |  | 1,684 |  | 1,645 |  | 0.7 |  |  | 2.4 |
International |  | 1,230 |  | 1,263 |  | 1,198 |  | (2.6) |  |  | 5.4 |
Worldwide |  | 2,926 |  | 2,947 |  | 2,843 |  | (0.7) |  |  | 3.7 |
Surgery |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,003 |  | 4,031 |  | 3,897 |  | (0.7) |  |  | 3.4 |
International |  | 5,842 |  | 6,006 |  | 5,793 |  | (2.7) |  |  | 3.7 |
Worldwide |  | 9,845 |  | 10,037 |  | 9,690 |  | (1.9) |  |  | 3.6 |
ADVANCED |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,838 |  | 1,833 |  | 1,784 |  | 0.2 |  |  | 2.8 |
International |  | 2,650 |  | 2,837 |  | 2,785 |  | (6.6) |  |  | 1.9 |
Worldwide |  | 4,488 |  | 4,671 |  | 4,569 |  | (3.9) |  |  | 2.2 |
GENERAL |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,165 |  | 2,198 |  | 2,113 |  | (1.5) |  |  | 4.0 |
International |  | 3,192 |  | 3,168 |  | 3,008 |  | 0.8 |  |  | 5.3 |
Worldwide |  | 5,358 |  | 5,366 |  | 5,121 |  | (0.2) |  |  | 4.8 |
Vision |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,128 |  | 2,086 |  | 1,990 |  | 2.0 |  |  | 4.8 |
International |  | 3,018 |  | 2,986 |  | 2,859 |  | 1.1 |  |  | 4.5 |
Worldwide |  | 5,146 |  | 5,072 |  | 4,849 |  | 1.5 |  |  | 4.6 |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,684 |  | 1,626 |  | 1,522 |  | 3.6 |  |  | 6.8 |
International |  | 2,049 |  | 2,076 |  | 2,022 |  | (1.3) |  |  | 2.7 |
Worldwide |  | 3,733 |  | 3,702 |  | 3,543 |  | 0.8 |  |  | 4.5 |
SURGICAL |  |  |  |  |  |  |  |  |  |
U.S. |  | 444 |  | 460 |  | 468 |  | (3.4) |  |  | (1.8) |
International |  | 969 |  | 910 |  | 837 |  | 6.5 |  |  | 8.6 |
Worldwide |  | 1,413 |  | 1,370 |  | 1,306 |  | 3.2 |  |  | 4.9 |
|  | Sales to Customers |  | % Change
(Dollars in Millions) |  | 2024 |  | 2023 |  | 2022 |  | ’24 vs. ’23 |  | ’23 vs. ’22
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |
U.S. |  | 16,332 |  | 15,275 |  | 13,377 |  | 6.9 |  |  | 14.2 |
International |  | 15,525 |  | 15,125 |  | 14,050 |  | 2.6 |  |  | 7.7 |
Worldwide |  | 31,857 |  | 30,400 |  | 27,427 |  | 4.8 |  |  | 10.8 |
WORLDWIDE |  |  |  |  |  |  |  |  |  |
U.S. |  | 50,302 |  | 46,444 |  | 41,981 |  | 8.3 |  |  | 10.6 |
International |  | 38,519 |  | 38,715 |  | 38,009 |  | (0.5) |  |  | 1.9 |
Worldwide |  | $88,821 |  | 85,159 |  | 79,990 |  | 4.3 | % |  | 6.5 |
* percentage greater than 100% or not meaningful (1)Previously referred to as Interventional Solutions (2)Acquired on December 22, 2022 (3)Acquired on May 31, 2024
Reconciliation of Operating Profit (Loss) from Segments to Consolidated |
|  | Income Before Tax by Segment
(Dollars in Millions) |  | 2024 (3) | 2023 (4) | 2022 (5)
|  | Innovative Medicine | MedTech | Total | Innovative Medicine | MedTech | Total | Innovative Medicine | MedTech | Total
Sales to customers |  | $56,964 | 31,857 |  | 54,759 | 30,400 |  | 52,563 | 27,427 |
Cost of products sold |  | 14,036 | 13,345 |  | 13,715 | 12,722 |  | 14,066 | 10,397 |
Selling, marketing and administrative |  | 10,906 | 10,812 |  | 9,842 | 10,476 |  | 9,714 | 9,537 |
Research and development expense |  | 13,529 | 3,703 |  | 11,963 | 3,122 |  | 11,642 | 2,493 |
Other segment items (1) |  | (426) | 257 |  | 993 | (589) |  | 1,494 | 553 |
Segment income before tax |  | $18,919 | 3,740 | 22,659 | 18,246 | 4,669 | 22,915 | 15,647 | 4,447 | 20,094
Less: Expense not allocated to segments (2) |  |  |  | 5,972 |  |  | 7,853 |  |  | 735
Worldwide total |  |  |  | $16,687 |  |  | 15,062 |  |  | 19,359
Schedule of Segment Reporting Information |
|  |  |  | Identifiable Assets
(Dollars in Millions) |  |  |  |  |  |  |  | 2024 |  | 2023
Innovative Medicine |  |  |  |  |  |  |  | $57,070 |  | 58,324
MedTech |  |  |  |  |  |  |  | 84,322 |  | 74,710
Total |  |  |  |  |  |  |  | 141,392 |  | 133,034
General corporate (6) |  |  |  |  |  |  |  | 38,712 |  | 34,524
Worldwide total |  |  |  |  |  |  |  | $180,104 |  | 167,558
|  | Additions to Property, Plant & Equipment |  | Depreciation and Amortization
(Dollars in Millions) |  | 2024 |  | 2023 |  | 2022 |  | 2024 |  | 2023 |  | 2022
Innovative Medicine |  | $1,710 |  | 1,653 |  | 1,374 |  | $3,760 |  | 3,847 |  | 3,687
MedTech |  | 2,443 |  | 2,372 |  | 2,120 |  | 3,237 |  | 2,943 |  | 2,302
Segments total |  | 4,153 |  | 4,025 |  | 3,494 |  | 6,997 |  | 6,790 |  | 5,989
Discontinued operations |  | — |  | 162 |  | 303 |  | — |  | 383 |  | 641
General corporate |  | 271 |  | 356 |  | 212 |  | 342 |  | 313 |  | 340
Worldwide total |  | $4,424 |  | 4,543 |  | 4,009 |  | $7,339 |  | 7,486 |  | 6,970
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas |
|  | Sales to Customers |  | Long-Lived Assets (7)
(Dollars in Millions) |  | 2024 |  | 2023 |  | 2022 |  | 2024 |  | 2023
United States |  | $50,302 |  | 46,444 |  | 41,981 |  | $70,670 |  | 54,832
Europe |  | 20,212 |  | 20,410 |  | 20,664 |  | 27,267 |  | 31,616
Western Hemisphere excluding U.S. |  | 4,714 |  | 4,549 |  | 4,108 |  | 1,728 |  | 1,491
Asia-Pacific, Africa |  | 13,593 |  | 13,756 |  | 13,237 |  | 1,454 |  | 1,500
Segments total |  | 88,821 |  | 85,159 |  | 79,990 |  | 101,119 |  | 89,439
General corporate |  |  |  |  |  |  |  | 1,217 |  | 1,192
Other non long-lived assets |  |  |  |  |  |  |  | 77,768 |  | 76,927
Worldwide total |  | $88,821 |  | 85,159 |  | 79,990 |  | $180,104 |  | 167,558
See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all three segments that represented approximately 18.9%, 15.0%, and 13.8% of the total gross revenues. (1)Other segment expenses for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development. (2)Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7 billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $0.4 billion. (3)Innovative Medicine segment income before tax includes: •Acquired in-process research & development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) •Monetization of royalty rights of $0.3 billion •Litigation expense of $0.3 billion primarily related to Risperdal Gynecomastia •An intangible asset impairment charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. •A restructuring related charge of $0.1 billion •One-time COVID-19 Vaccine manufacturing exit related costs of $0.1 billion •Favorable changes in the fair value of securities of $0.1 billion MedTech segment income before tax includes: •Acquisition and integration related costs of $1.0 billion primarily related to the acquisition of Shockwave •Acquired in-process research and development expense of $0.5 billion from the V-Wave acquisition •A gain of $0.2 billion related to the Acclarent divestiture •A Medical Device Regulation charge of $0.2 billion •A restructuring related charge of $0.2 billion (4)Innovative Medicine segment income before tax includes: •One-time COVID-19 Vaccine manufacturing exit related costs of $0.7 billion •A restructuring related charge of $0.5 billion •Unfavorable changes in the fair value of securities of $0.4 billion •Favorable litigation related items of $0.1 billion •Loss on divestiture of $0.2 billion. •An intangible asset impairment charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. MedTech segment income before tax includes: •Acquired in-process research and development expense of $0.4 billion related to the Laminar acquisition in 2023 •A restructuring related charge of $0.3 billion •Acquisition and integration related costs of $0.2 billion primarily related to the acquisition of Abiomed •A Medical Device Regulation charge of $0.3 billion •Income from litigation settlements of $0.1 billion (5)Innovative Medicine segment income before tax includes: •One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion •An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS •Litigation expense of $0.1 billion •Unfavorable changes in the fair value of securities of $0.7 billion •A restructuring related charge of $0.1 billion MedTech segment income before tax includes: •Litigation expense of $0.6 billion primarily for pelvic mesh related costs •A restructuring related charge of $0.3 billion •Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed •A Medical Device Regulation charge of $0.3 billion (6) General corporate includes cash, cash equivalents, marketable securities and other corporate assets. (7)Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $20,518 and $19,898, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $81,818 and $70,733, respectively.

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration